吉西他滨联合顺铂治疗晚期非小细胞肺癌42例观察

目的: 观察国产吉西他滨(GEM)联合顺铂(DDP)治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法: 有明确的病理和(或)细胞学诊断的42例晚期非小细胞肺癌患者,用吉西他滨1g/m2静脉滴注,d₁、d₈;顺铂30mg/m2静脉滴注,d₁~d₃。每21天为一周期,治疗2周期以上评价其疗效及毒副反应。结果: 完全缓解1例(腺癌),部分缓解17例,稳定16例,进展8例,有效率为42.9%。主要毒副反应为Ⅰ、Ⅱ度骨髓抑制71.4%(30/42)及恶心呕吐,但没有严重的Ⅳ度损害;无明显的肝肾功能损害。结论: 国产吉西他滨联合顺铂化疗方案治疗晚期非小细胞肺癌有较好的疗效,且耐受性较好。

Combination of gemcitabine and cisplatin in treatment of advanced non-small-cell lung cancer

Objective: To evaluate the clinical efficacy and toxicity of combined gemcitabine and cisplatin in treatment of advanced non-small-cell lung cancer (NSCLC). Methods: Forty-two patients pathologically confirmed as stage Ⅲ or Ⅳ NSCLC were given Gemcitabine on d₁, and d₈ at a dose of 1 g/m2 and cisplatin on d_1-3 at a dose of 30 mg/m2. The chemotherapy was repeated every 21 days. Each patient was treated for at least 2 cycles. Results: Complete response was observed in 1case, partial response in 17 cases, no response in 16 cases and progression in 8 cases. The overall response rate was 42.9%. The main toxicities were gradeⅠ-Ⅱmyelosuppression, nausea and vomiting;however, there was no severe grade Ⅳ damage or obvious liver and kidney damage. Conclusions: Combination of gemcitabine and cisplatin is effective and well-tolerated in the treatment of advanced NSCLC.